The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer.

Medicine (Baltimore) · 2018 · PMC5902288 · PMID 29620661

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The median PFS (6.5 months vs 2.4 months) and median OS (15.4 months vs 9.2 months) were numerically better in the responder than in the non-responder group although their improvement did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.